Clinical trials: Epithelial Ovarian Cancer
Advanced Ovarian Cancer, Platinum-resistant Ovarian Cancer
A Study of MOv18 IgE in Patients With Solid Tumours That Express Folate Receptor Alpha
EPS101-10-02 is a Phase Ib open label, multicentre clinical trial comprising of a Dose Escalation phase (Part 1) followed by a Dose Expansion phase (Part 2) of MOv18 IgE in patients with folate receptor alpha-expressing (5% or…
- Conditions
- Advanced Ovarian Cancer, Platinum-resistant Ovarian Cancer, Triple Negative Breast Cancer (TNBC), Triple -Negative Breast Cancer
- Trial name
- NCT06547840
- Testing
- MOv18 IgE
- Where
- 7 sites in United Kingdom
- Volunteers
- 45 people
- Sponsor
- Epsilogen Ltd
Ovarian Cancer
CT Antigen TCR-redirected T Cells for Ovarian Cancer.
This study, will take a subject's "T cells" and "teach" them to be able to recognize and attack the ovarian cancer cells. This is done by putting in a gene or genetic material that will change how a subject's T cells work and…
- Trial name
- NCT01567891
- Testing
- NYESO-1c259 T cells
- Where
- 5 sites in United States
- Volunteers
- 9 people
- Sponsor
- Adaptimmune
Solid Tumors Stage II, Stage III and Stage IV, Breast Cancer
Experimental Therapeutic Cancer Vaccine Created In-situ in Patients With Stage II-Stage IV Cancer
A Phase I/II study of an in-situ therapeutic cancer vaccine. Vaccines contain a source of antigen and and adjuvant. In this study the source of tumor antigen comes from the killing of a selected tumor by cryoablation (killing…
- Conditions
- Solid Tumors Stage II, Stage III and Stage IV, Breast Cancer, Colorectal Cancer, Prostate Cancer
- Trial name
- NCT01065441
- Testing
- AlloStim, Cryoablation
- Where
- Israel
- Volunteers
- 9 people
- Sponsor
- Michael Har-Noy
Ovarian Cancer
Characterizing the Cross-sectional Approach to Ovarian Cancer: Genetic Testing of BRCA
The multi-centered, cross-sectional investigations shall be conducted in this study with the objective of identifying the ownership ratio of gBRCAm on the newly diagnosed patients with epithelial ovarian cancer, primary…
- Trial name
- CHARLOTTE (NCT03229122)
- Where
- 35 sites in Japan
- Volunteers
- 446 people
- Sponsor
- AstraZeneca
Ovarian Cancer, AIDS-related Kaposi Sarcoma
Doxil/Caelyx BE Study
The aim of this study is to demonstrate the bioequivalence of DOXIL/CAELYX, 40 mg/m2 (IV infusion over 90 minutes) between two manufacturing facilities.
- Conditions
- Ovarian Cancer, AIDS-related Kaposi Sarcoma, Multiple Myeloma, Metastatic Breast Cancer
- Trial name
- NCT05567601
- Testing
- DOXIL/CAELYX
- Where
- 14 sites in India
- Volunteers
- 36 people
- Sponsor
- Baxter Healthcare Corporation
Ovarian Cancer
Optimal Timing of BR55 CEUS of the Ovaries
This is an exploratory, single center, open label, prospective study of BR55 to determine the optimal phase of the menstrual cycle for performing BR55 contrast-enhanced ultrasonography (CEUS) of the target ovary in premenopausal…
- Trial name
- NCT04248153
- Testing
- BR55
- Where
- United States
- Volunteers
- 3 people
- Sponsor
- Bracco Diagnostics, Inc
Head & Neck Cancer, Pancreas Carcinoma
SL-28 for Advanced Solid Tumours
Second Life Therapeutics is developing SL-28, an allogeneic, non-genetically modified cell-based therapy for the treatment of advanced solid tumours.
- Conditions
- Head & Neck Cancer, Pancreas Carcinoma, Pancreas Cancer, Metastatic, Lung Adenocarcinoma
- Trial name
- NCT07341737
- Testing
- SL-28
- Where
- 3 sites in Australia
- Volunteers
- 60 people
- Sponsor
- Second Life Therapeutics
Stage III Ovarian Cancer, Stage IV Ovarian Cancer
Salvage Ovarian FANG™ Vaccine + Bevacizumab
This is a Phase II study of Vigil™ autologous tumor cell vaccine integrated with bevacizumab. All patients will have had Vigil™ prepared and stored from initial primary surgical debulking.
- Trial name
- NCT01551745
- Testing
- Vigil™ Vaccine, Bevacizumab
- Where
- United States
- Volunteers
- 5 people
- Sponsor
- Gradalis, Inc.
Advanced Solid Tumors
A Study of Budigalimab (ABBV-181) in Participants With Advanced Solid Tumors
This is an open-label, Phase I, dose-escalation study to determine the recommended Phase 2 dose (RPTD), maximum tolerated dose (MTD), and evaluate the safety and pharmacokinetic (PK) profile of budigalimab.
- Trial name
- NCT03000257
- Testing
- Venetoclax, Rovalpituzumab Tesirine, ABBV-181
- Where
- 26 sites in United States, Australia and 8 more
- Volunteers
- 182 people
- Sponsor
- AbbVie
Ovarian Cancer, Peritoneal Cancer
A Study of Single Agent Pemetrexed Disodium in Treating Patients With Recurrent or Persistent Ovarian or Primary Peritoneal Cancer
The primary purpose of this trial is to estimate the drug effect on tumors in patients with ovarian or primary peritoneal cancers. Patients will receive Pemetrexed every 21 days until disease progression or unacceptable toxicity.
- Trial name
- NCT00461786
- Testing
- pemetrexed
- Where
- United States
- Volunteers
- 51 people
- Sponsor
- Eli Lilly and Company
Ovarian Cancer
A Study in Patients With Persistent or Recurrent Epithelial Ovarian or Primary Peritoneal Carcinoma
The purpose of this study is to determine the overall response rate, time to progression, and 1 yr survival with cetuximab in patients with ovarian or primary peritoneal carcinoma.
- Trial name
- NCT00082212
- Testing
- Cetuximab
- Where
- 5 sites in United States
- Volunteers
- 25 people
- Sponsor
- Eli Lilly and Company
HER2-Expressing Solid Tumors
Safety, Pharmacokinetics, Pharmacodynamics and Preliminary Efficacy of MT-304 in Adults With Advanced HER2-Expressing Solid Tumors
This clinical trial is designed to evaluate the safety, pharmacokinetics, pharmacodynamics, and preliminary efficacy of MT-304 in adults with advanced HER2-expressing solid tumors.
- Trial name
- NCT07334119
- Testing
- MT-304, MT-304 + Nivolumab
- Where
- 7 sites in Australia
- Volunteers
- 60 people
- Sponsor
- Myeloid Therapeutics
Ovarian Cancer, Fallopian Tube Cancer
A Study to Evaluate the Efficacy and Safety of Sacituzumab Tirumotecan (MK-2870) Maintenance Treatment Versus Standard of Care in Participants With Platinum-sensitive Recurrent Ovarian Cancer (MK-2870-022/TroFuse-022/ENGOT-ov84/GOG-3103)
The main goals of this study are to learn about the safety of sacituzumab tirumotecan with bevacizumab and if people tolerate it; and if people who take sacituzumab tirumotecan with or without bevacizumab live longer without the…
- Conditions
- Ovarian Cancer, Fallopian Tube Cancer, Primary Peritoneal Cancer
- Trial name
- NCT06824467
- Testing
- Sacituzumab tirumotecan, Bevacizumab, H1 receptor antagonist
- Where
- 198 sites in United States, Argentina and 27 more
- Volunteers
- 770 people
- Sponsor
- Merck Sharp & Dohme LLC
Solid Tumor, Gastric Cancer
Safety, Pharmacokinetics, Pharmacodynamics, and Preliminary Efficacy Trial of BNT141 in Patients With Unresectable or Metastatic CLDN18.2-positive Gastric, Pancreatic, Ovarian and Biliary Tract Tumors
This study was planned as an open-label, multi-site, Phase I/IIa dose escalation, safety, and pharmacokinetic (PK) trial of BNT141 followed by expansion cohorts in patients with Claudin 18.2 (CLDN18.2)-positive tumors.
- Conditions
- Solid Tumor, Gastric Cancer, Gastroesophageal Junction Adenocarcinoma, Esophageal Adenocarcinoma
- Trial name
- NCT04683939
- Testing
- BNT141, Nab-paclitaxel, Gemcitabine
- Where
- 7 sites in United States, Canada
- Volunteers
- 13 people
- Sponsor
- BioNTech SE
Advanced Solid Tumours With Androgen Receptor Pathway as a Potential Factor
Phase I Open Label Dose Escalation Study to Investigate the Safety & Pharmacokinetics of AZD5312 in Patients With Androgen Receptor Tumors
This is a first time in man (FTIM), Phase I study to determine the Maximum Tolerated Dose, Recommended Phase 2 Dose, safety, tolerability and Pharmacokinetics of AZD5312.
- Trial name
- NCT02144051
- Testing
- AZD5312
- Where
- 4 sites in United States, United Kingdom
- Volunteers
- 32 people
- Sponsor
- AstraZeneca
Solid Tumor, Lymphoma
Study of Oral PXD101 in Patients With Advanced Solid Tumors or Lymphoma
This is a Phase I dose escalation study of PXD101 administered orally. Oral belinostat will be given once or twice daily at various dosing schedules to patients with solid tumors.
- Trial name
- NCT00413075
- Testing
- oral belinostat
- Where
- 6 sites in United States, Denmark and 1 more
- Volunteers
- 121 people
- Sponsor
- Valerio Therapeutics
Ovarian Cancer, Cervical Cancer
A Prospective Study to Evaluate the Clinical Performance and Safety of the SIRIUS Endoscope System in Laparoscopic Gynecological Surgery.
Precision Robotics' Sirius Robotic Flexible Endoscopic System is a new fully integrated compact 3D laparoscopic camera system with a disposable single-use flexible tip that can change its viewing direction.
- Conditions
- Ovarian Cancer, Cervical Cancer, Gynecologic Cancer
- Trial name
- NCT05318625
- Testing
- Gynaecological laparoscopic surgery (Sirius System)
- Where
- Hong Kong
- Volunteers
- 30 people
- Sponsor
- Precision Robotics (Hong Kong) Limited
Ovarian Cancer Recurrent
A Study of Doxorubicin Hydrochloride Liposome Injection in Subjects With Ovarian Cancer.
Bioequivalence study is proposed to be carried out on patients of ovarian cancer, who are already receiving or who in the opinion of their treating physicians are candidates for Doxorubicin liposomal injection therapy .
- Trial name
- NCT03681548
- Testing
- Doxorubicin Hydrochloride Liposome Injection
- Where
- 15 sites in India
- Volunteers
- 52 people
- Sponsor
- Ayana Pharma Ltd.,
Colorectal Cancer, Gastric Cancers
Study to Evaluate the Diagnostic Performance of GEH300079 (68Ga) Injection PET/CT for Detection of PC in Patients With Colorectal, Gastric, Ovarian, or Pancreatic Cancers (PERISCOPE)
This study is a Phase 2/3, prospective, multicenter, open-label, non-randomized clinical trial, in which GEH300079 (68Ga) PET/CT images will be acquired in patients with primary colorectal, gastric, ovarian, or Pancreatic Ductal…
- Conditions
- Colorectal Cancer, Gastric Cancers, Ovarian Cancers, Pancreatic Ductal Adenocarcinoma
- Trial name
- NCT07219238
- Testing
- GEH300079 (68Ga) Injection Positron-Emission Tomography (PET)/Computed Tomography (CT)
- Where
- 2 sites in United States, Sweden
- Volunteers
- 175 people
- Sponsor
- GE Healthcare
Ovarian Cancer, Endometrial Cancer
Phase 1 Study to Assess Safety, Tolerability, Pharmacokinetics, Immunogenicity, and Antitumor Activity of ARR-002 in Advanced or Metastatic Ovarian or Endometrial Cancer.
This is a Phase 1 study to assess safety, tolerability, pharmacokinetics, immunogenicity, and antitumor activity of ARR-002 in advanced or metastatic ovarian or endometrial cancer.
- Conditions
- Ovarian Cancer, Endometrial Cancer, Platinum-resistant Ovarian Cancer (PROC), Metastatic Ovarian Cancer
- Trial name
- NCT07755436
- Testing
- ARR-002
- Where
- 6 sites in United States
- Volunteers
- 180 people
- Sponsor
- ArriVent BioPharma, Inc.
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.